86
Participants
Start Date
April 21, 2021
Primary Completion Date
November 11, 2022
Study Completion Date
November 11, 2022
LY3484356
Administered orally.
Institut Jules Bordet, Brussel - Capital
Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven
Helios Kliniken Schwerin, Schwerin
Hospital General Universitario Gregorio Marañon, Madrid
Hospital Madrid Norte Sanchinarro, Madrid
Winship Cancer Center Emory University, Atlanta
Sarah Cannon Research Institute SCRI, Nashville
Northwestern Memorial Hosptial, Chicago
Washington University School of Medicine, St Louis
Baylor College of Medicine, Houston
University of Texas MD Anderson Cancer Center, Houston
Klinikum der Universitaet Muenchen, München
Universitätsklinikum Erlangen, Erlangen
Hôpital René Huguenin, Saint-Cloud
Massachusetts General Hospital, Boston
University of Vermont Medical Center, Burlington
Hospital Clinic I Provincial, Barcelona
The Royal Cornwall Hospital, Truro
Barts Cancer Institute, London
Eli Lilly and Company
INDUSTRY